Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8367063
APP PUB NO 20110052604A1
SERIAL NO

12782376

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • E. R. SQUIBB & SONS, L.L.C.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Boyle, William J Malibu, US 112 17744
Elliott, Robin L Newbury Park, US 6 140
Huang, Haichun Fremont, US 118 7366
Martin, Frank Newbury Park, US 37 1570
Medlock, Eugene Westlake, US 20 500
Sullivan, John K Newbury Park, US 20 768

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 5, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00